Latest News
OrganaBio and RxMP Therapeutics partner to advance RMP-402 haemostatic drug product
23 April 2026 - Blood and cell products and services company OrganaBio LLC and RxMP Therapeutics Inc, a late pre-clinical development stage therapeutics company developing novel therapies for the rapid control of severe haemorrhage, on Wednesday anno...
Université Laval and Glycovax Pharma agree exclusive global licence to develop innovative galectin-3 inhibitors
23 April 2026 - Canadian biopharmaceutical company Glycovax Pharma Inc announced on Wednesday an exclusive global licence agreement with Université Laval in Quebec, granting Glycovax the rights to develop and commercialise a family of compound...
Thryv Therapeutics doses first patients in Wave II clinical study for Long QT Syndrome; THRV-1268 receives FDA Fast Track Designation
23 April 2026 - Thryv Therapeutics Inc, a Canada-based, clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, ...
WuXi Biologics receives South Korean certification for commercial manufacturing of bispecific antibody therapeutics
23 April 2026 - WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Thursday that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5 (MFG5), ...
Labcorp launches FDA-approved companion diagnostic to identify ovarian cancer patients' KEYTRUDA eligibility
23 April 2026 - US laboratory services provider Labcorp (NYSE:LH) announced on Wednesday the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the US Food and Drug Administration (...